Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Announces Major FOB Initiative With Its New Business Unit

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.

You may also be interested in...



Merck's Second-To-Market Renflexis Biosimilar Priced Below The First

Merck & Co. launched Renflexis in the US, marking the first time two biosimilars will compete for share against a brand, in this case J&J's Remicade.

Merck's Second-To-Market Renflexis Biosimilar Priced Below The First

Merck & Co. launched Renflexis in the US, marking the first time two biosimilars will compete for share against a brand, in this case J&J's Remicade.

Deals Of The Week Wonders: What Does Merck’s Latest Biosimilar Move Really Mean?

Plus a look at Roche/Chiasma, Chiesi/Cornerstone, Eisai/Valeant and more

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel